MIVEGEC, Montpellier University, CNRS, IRD, Montpellier, France; Medical Biology Laboratory, Institut Pasteur du Cambodge, Phnom Penh, Cambodia; LMI Drug Resistance in Southeast Asia, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Medical Biology Laboratory, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
J Glob Antimicrob Resist. 2024 Sep;38:236-244. doi: 10.1016/j.jgar.2024.06.017. Epub 2024 Jul 14.
Despite the critical importance of colistin as a last-resort antibiotic, limited studies have investigated colistin resistance in human infections in Cambodia. This study aimed to investigate the colistin resistance and its molecular determinants among Extended-spectrum beta-lactamase (ESBL)- and carbapenemase-producing (CP) Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. coli) isolated in Cambodia between 2016 and 2020.
E. coli (n = 223) and K. pneumoniae (n = 39) were tested for colistin minimum inhibitory concentration (MIC) by broth microdilution. Resistant isolates were subjected to polymerase chain reaction (PCR) for detection of mobile colistin resistance genes (mcr) and chromosomal mutations in the two-component system (TCS).
Eighteen isolates (10 K. pneumoniae and 8 E. coli) revealed colistin resistance with a rate of 5.9% in E. coli and 34.8% in K. pneumoniae among ESBL isolates, and 1% in E. coli and 12.5% in K. pneumoniae among CP isolates. The resistance was associated with mcr variants (13/18 isolates, mcr-1, mcr-3, and mcr-8.2) and TCS mutations within E. coli and K. pneumoniae, with the first detection of mcr-8.2 in Cambodia, the discovery of new mutations potentially associated to colistin resistance in the TCS of E. coli (PhoP I47V, PhoQ N352K, PmrB G19R, and PmrD G85R) and the co-occurrence of mcr genes and colistin resistance conferring TCS mutations in 11 of 18 isolates.
The findings highlight the presence of colistin resistance in ESBL- and CP- Enterobacteriaceae involved in human infections in Cambodia as well as chromosomal mutations in TCS and the emergence of mcr-8.2 in E. coli and K. pneumoniae. It underscores the need for continuous surveillance, antimicrobial stewardship, and control measures to mitigate the spread of colistin resistance.
多黏菌素作为一种最后手段的抗生素至关重要,但在柬埔寨,针对人类感染中多黏菌素耐药的研究有限。本研究旨在调查 2016 年至 2020 年期间在柬埔寨分离的产超广谱β-内酰胺酶(ESBL)和碳青霉烯酶(CP)肺炎克雷伯菌(K. pneumoniae)和大肠埃希菌(E. coli)中的多黏菌素耐药情况及其分子决定因素。
采用肉汤微量稀释法检测 E. coli(n=223)和 K. pneumoniae(n=39)的多黏菌素最小抑菌浓度(MIC)。对耐药分离株进行聚合酶链反应(PCR)检测移动多黏菌素耐药基因(mcr)和两成分系统(TCS)中的染色体突变。
18 株分离株(10 株 K. pneumoniae 和 8 株 E. coli)表现出多黏菌素耐药,其中 ESBL 分离株中 E. coli 的耐药率为 5.9%,K. pneumoniae 的耐药率为 34.8%,CP 分离株中 E. coli 的耐药率为 1%,K. pneumoniae 的耐药率为 12.5%。耐药与 mcr 变异体(13/18 株,mcr-1、mcr-3 和 mcr-8.2)和 E. coli 和 K. pneumoniae 中的 TCS 突变相关,在柬埔寨首次检测到 mcr-8.2,发现了与 TCS 中多黏菌素耐药相关的新突变(E. coli 的 PhoP I47V、PhoQ N352K、PmrB G19R 和 PmrD G85R),在 18 株分离株中的 11 株中 mcr 基因和多黏菌素耐药 TCS 突变共存。
本研究结果表明,柬埔寨人感染中 ESBL 和 CP 肠杆菌科中存在多黏菌素耐药,以及 TCS 中的染色体突变和 E. coli 和 K. pneumoniae 中 mcr-8.2 的出现。这突显了持续监测、抗菌药物管理和控制措施的必要性,以减轻多黏菌素耐药的传播。